poisar

Stocks · News reference

Longeveron Retains Lucid Capital Markets As Financial Advisor To Explore Strategic Opportunities Including A Potential Merger

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

LGVN
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial

    Longeveron reported updated results from its ELPIS II Phase 2b clinical trial for laromestrocel in infants with hypoplastic left heart syndrome (HLHS), noting that while the primary endpoint was not met, the therapy showed significant results in reducing major adverse cardiac events.

    LGVN
  2. SEC EDGAR

    8-K filing — Longeveron Inc. (LGVN)

    Filed: 2026-10-26 AccNo: 0001213900-26-112508 Size: 265 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

    LGVN